OR WAIT null SECS
Company pursues ‘bench to bedside’ commercialization services
Nolan, former chief commercial officer and SVP at Marathon Pharmaceuticals, is the new president of Dohmen Life Science Services (DLSS), the company announced. DLSS, which traces its roots back to a nineteenth-century family-run pharmacy and wholesaling business in Milwaukee, has evolved an unusual business model that can partner with a pharma client to develop a new drug, take it through approval, and then handle its distribution, dispensing and patient support; all with an emphasis on orphan drugs for rare diseases, a model that it calls “bench to bedside.”
“Finding the right expertise at the right time in a product's development life cycle can be distracting and difficult for companies that want to stay focused on bringing great products to market and building strong patient relationships. The DLSS model offers the industry a single resource to stay lean, act fast, mitigate risk and keep growing," said Nolan, in a statement.
He will report to Cynthia LaConte, Dohmen CEO.